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Challenging the Biomedical Notion of ‘Active Substance’:
The Botanical Plasticity of Tibetan Medical Formulas

Herbert Schwabl
Jan M. A. van der Valk

Sowa Rigpa (Tibetan medicine) has been
practiced across vast regions of Central
and South Asia for centuries. In this medical
tradition, it is common practice to dynamically
adapt the mainly herbal formulas according to
the regional flora and local conditions, and to
use local variants of ingredients. Consequently,
one Tibetan ingredient name within a specific
formula can signify a variety of therapeutically
fitting botanical items, which appear quite
different from the perspective of modern
taxonomy. This has led many researchers to
understand the botanical plasticity of Tibetan
medical formulas as misidentifications. We
develop an alternative approach, exploring the
advantages of this plasticity as a necessary
practice to fulfill economic and therapeutic
needs. This perspective piece questions
the biomedical paradigm of single ‘active
substances,’ since botanically unrelated plants
with different chemical compositions can
be similarly therapeutically effective. From
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a systems biology perspective, network
pharmacology lets us understand the
correspondence of illness and medicine as a
semiotic process in which herbal formulations
act via their ‘pleiotropic signatures’: complex
webs of signal pathways that connect and act
on multiple levels of organization in the body.
Keywords: Sowa Rigpa, Tibetan herbal formulas, network
pharmacology, active substance, substitution.

Introduction
Herbal medicines have historically been of central
importance for human health. Although the global
pharmaceutical industry has reduced its overall funding
for natural products research over the last decade (Laird
2013), the current market for phytomedicinal products—
especially in and from countries such as India (Booker et
al. 2016) and China (Dang et al. 2016)—is booming. New
trends in poly-pharmacology, systems biology (van der
Greef 2011), personalized medicine, and evidence-based
phytotherapy aim to capture their complex effects as we
enter a post-antibiotic area in the face of alarming antibiotic resistance (Kahrstrom 2013), and to grapple with
aging populations, diseases of affluence, and multimorbidity. The Swiss company PADMA Inc., which produces
Tibetan herbal formulas according to Good Manufacturing
Practices (GMP), is at the forefront of these cutting-edge
developments with regard to Sowa Rigpa (Schwabl et al.
2013; Zick et al. 2009). Yet this company has also experienced the many limitations, struggles, and frustrations of
getting Tibetan medicines in European markets (Schwabl
and Vennos 2015; van der Valk 2017: 253-286). The
far-reaching influence of Big Pharma on politicians and
regulators has led to well-known commercial, scientific,
and regulatory biases on their behalf (see for instance
Davis and Abraham 2013). These ‘Big Regulations’ also
presume and enforce universal applicability of a biomedical pharmacology geared towards the development of
chemical medicines made up of one or a few highly purified and concentrated ‘active pharmaceutical ingredients.’
In this perspective piece, we challenge this notion of
‘active substance’ by foregrounding the botanical plasticity
of Tibetan medical formulas in local practice and across
space and time. Sowa Rigpa—the emerging umbrella term
for ‘Tibetan medicine’—dates back at least to the twelfth
century, when the codification of the foundational medical
text the Four Treatises was initiated (Yang Ga 2014). It has
been practiced for centuries in highly diverse settings,
from rural master-disciple lineages to monasteries and
modern medical hospitals. Today, Sowa Rigpa’s regional
distribution extends across the Qinghai-Tibet Plateau, the
Himalayan region (including Ladakh, India, Nepal, and
Bhutan), and north up to Mongolia and Buryatia. Covering
these varied contexts, a solid body of ethnographic and
historical studies (e.g., Adams et al. 2011; Craig et al. 2010;
Hofer 2014; Pordié 2008; Samuel 2013; Schrempf 2007) indicates that Tibetan medical formulas—largely of herbal and
mineral composition—are part of a time-tested and socially
validated ethnomedical tradition. More specifically,
anthropologist Calum Blaikie (2015) has demonstrated

the inherent multiplicity of so-called ‘classical formulas,’
resulting in innumerable variants or avatars in actualized
practice. In doing so, Blaikie convincingly argues against
the view that these multiple versions of ‘the same’ drug
“represent the corruption of classical purity or inauthentic
approximations of a static ideal” (Blaikie 2015: 12). Gerke’s
(2018) analysis of the authorship and intertextuality of the
genre of Tibetan formulas also confirms that knowledge
transmission is typically fluid and dynamic in the sense
that it relies on re-interpretation, reformulation, and the
addition of ‘personal signatures.’
Nonetheless, a number of institutional and scholarly
discussions have focused on the plasticity of Tibetan
formulas in a derogatory way, relying on terms such as
the ‘misidentification’ of ingredients, deviations from an
‘original’ formula, focusing on the inferiority of ‘substitutes,’ and the need for standardization and a unified
pharmacopoeia (Dawa 1999, 2009; Kletter and Kriechbaum
2001; Ministry of Health (PRC) 1998; PRU 2009).1 See, for
instance, Fernand Meyer (1988: 37, translated from French)
for an early example:
Collections of ‘Tibetan’ medical material are made by teams
of unequal competence, in different epochs and conditions,
in regions often far apart from each other. They cannot
provide homogeneous material suitable for inclusion in such
a work [multi-language dictionaries of medicinal plants].
This explains why under the same Tibetan name we found
plants sometimes closely related, but often very different.
[...] According to what criteria would we be inclined to
prefer one determination to another?
This quote reveals an unjustified prejudice: that one
Tibetan ingredient name must correspond to a modern
Linnaean concept and be identified as one particular
plant, and that only this plant should be the basis of future
research (see also Molvray 1988; Kletter and Kriechbaum
2001). However, why should Sowa Rigpa pharmacology
follow the path of systematic botany? The preoccupation
with weeding out ‘geographical bias’ and ‘sources of
confusion’ (and diversity!) has its roots in the emergence
of modern pharmacy and pharmacognosy. It mirrors
the establishment of national pharmacopoeias, based
on earlier herbals, within Europe and beyond (see for
instance Griffin 2004 for the UK). This approach neglects
the inherent advantages of the dynamics of variability. The
pharmaceutically trained community is indeed puzzled
by this fact of plasticity. As a prerogative for any scientific
work the exact definition of each constituent of a formula
is demanded, which then leads to the quest of modern
pharmacology for the single chemical molecule, the ‘active
substance,’ responsible for therapeutic activity.
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The flexible use of a variety of plants in a functionally
similar manner, as seen in Sowa Rigpa practice, is a
challenge to accept from the perspective of modern
pharmacology. Our aim here is to explore the botanical
plasticity of Sowa Rigpa formulas—the botanically flexible
but functionally stable use of plants—in order to provide
a bridge between Tibetan medical principles and conventional chemistry, pharmacology, and biomedicine. From a
systems perspective2, the complex yet stable physiological
action profile of these variable mixtures defies attempts
at extreme standardization. Botanically and chemically
entirely different plant species may exhibit similar
signatures of action, especially when combined into multitarget ‘network medicines’ which mirror the complexity
of chronic diseases. We thus invite scholars and scientists
alike to approach potent substances semiotically in future
research; that is, from a functional rather than a strictly
material substance-based perspective. The authors recognize that Sowa Rigpa’s ‘pharmaceutical assemblage’ (Kloos
2017) is part of “emergent cosmopolitical technoscientific
worlds” (Fischer 2007: 573) that go beyond the purview
of Euro-American histories of ideas, even though “[t]he
history of almost all modern science […] must be understood as ‘science in a colonial context’” (Seth 2009: 374). By
validating and thinking through the botanical plasticity of
Tibetan medical formulas, we aim to decenter or provincialize the dominant place of the biomedical concept of
‘active substances’ in discussions on herbal medicines (cf.
Schwabl et al. 2016), both in general and specifically in
relation to the potency of multi-compound Asian medical
preparations. As such, we contribute to alternative theoretical models generated from within Asian Science and
Technology Studies (STS, cf. Fischer 2018), by working with
Sowa Rigpa (following Lin and Law’s work with Chinese
medicine, 2014, 2015). That is, we are carving out “a culturally Tibetan way of doing science” (Adams et al. 2011: 23).
Elements, Tastes, Potencies and the Composition
of Medicines
Roughly speaking, Sowa Rigpa divides diseases into hot
and cold disorders which are defined as a shift in the individual equilibrium of the three bodily dynamics, or nyépa
(nyes pa): lung, tripa and béken (rlung, mkhris pa, and bad kan;
often translated as ‘wind,’ ‘bile,’ and ‘phlegm’) (Donden
1986; Tsultrim and Dakpa 2009). According to the theory
of the five elements (’byung ba lnga), medicinal ingredients
can then be selected with characteristics that compensate
a disturbance in the patient’s elemental balance. Six tastes
define the activity of medicines: the elements of earth and
water generate the sweet taste, fire and earth produce
sour, water and fire produce salty, fire and wind produce
210 | HIMALAYA Spring 2019

pungent, water and wind produce bitter, and the earth
and wind elements together produce an astringent taste.
Used in a therapeutic setting, the sweet, sour, salty, and
hot tastes are seen to counteract lung disorders; bitter,
sweet, and astringent tastes treat tripa disorders; and
hot, sour, and salty tastes alleviate béken ailments. The
potency of medicines is elaborated further in the context
of the ‘eight powers’ (nus pa brgyad, which are heavy, oily,
cooling, blunt, light, rough, pungent, and sharp) as well as
‘seventeen qualities’ (yon tan bcu bdun) such as smoothness,
heaviness, warmth, oiliness, stability, and so forth.
The body of knowledge in Sowa Rigpa dealing with raw
materials and ‘medicine compounding’ or menjor (sman
sbyor), here simply denoted ‘Tibetan pharmacology,’ lists
numerous formulas composed of a variety of components
(Cardi 2005; Hofer 2014). Tibetan formulas characteristically contain more than three ingredients, often fifteen to
twenty, or even more. The components are mostly herbal
(e.g., roots, bark, leaves, flowers, fruits, and resins), which
are the focus of this piece. To a lesser extent, minerals
are used and, in rare cases, animal- or metal-based
substances. These raw materials are classified based on
the observed effects and their sensory properties such as
taste, texture, and color, which then relate back to the
elemental qualities and activities of the ingredients. In
Tibetan pharmacology, a substance is classified mainly
according to sensory qualities that contribute—as seen
from a systems perspective—to a specific functional profile
of action. Different components are then combined in a
formula to compensate for the disturbance of the individual equilibrium. The components are selected based on
their characterization according to three different aspects
(Nikolaev 1998): 1) hot or cold, 2) effect on the nyépa, and 3)
their organotropic properties (i.e., the directed activity of
the components towards a specific organ). From a modern
perspective, we translate this as a multi-dimensional
assignment of qualities to each ingredient and formula.
A Dynamic Tradition
The vast geographical domain where Sowa Rigpa is
practiced today covers a wide range of different ecological environments and habitats, with a high diversity of
plants as well as vegetation types (Boesi 2005, 2007; Lama
et al. 2001; Salick et al. 2006, 2009). Moreover, many raw
materials are acquired via different trade routes passing
through these regions (Akasoy et al. 2011; Blaikie 2014;
Saxer 2009). Across the Himalayan range, ethnobotanical
and ethnoecological studies have shattered the illusion
of one classic literary body implying a uniform practice,
especially when considering the interfaces with popular

and folk knowing practices (Ghimire et al. 2004; Salick
et al. 2006). It is common practice to adapt formulas
according to a specific environment and patient, and to
use local variants of ingredients (Blaikie 2014: 281-293;
Czaja 2017; Sabernig 2011). This traditional method has
allowed medical practitioners to respond to bottlenecks
related to availability, as well as to account for geographical and climatic differences. The formulas, therefore,
adapt to different regional, economic, and social demands
while maintaining their therapeutic effectiveness. Due to
this variability, one specific Tibetan formula with identically denominated ingredients may—from the modern
botanical point of view—contain one or more different
species or even genera, often without any direct taxonomic connection. This implies that these formulas have
a certain botanical plasticity, which characterizes Sowa
Rigpa as a dynamic tradition, across time and large geographies. Reasons for these variations may include (1) the
availability of raw materials, leading to different species
denominated with the same Tibetan name, (2) the wish to
improve a formula, or—one should not fully exclude—(3)
wrongly interpreting a textual formula (see Czaja 2013).
From the perspective of the individual Sowa Rigpa practitioner, the time-tested effectiveness of the used formulas
remains more or less undoubted. The therapeutic use and
range of indications may therefore be considered robust.
As Tibetan pharmacology assigns specific qualities to every
ingredient, it is possible and even likely that different
plants or substances present themselves with a similar set
of qualities; these ingredients are isomorph with respect
to their qualities.3 Consequently, it is possible within one
specific formula that one Tibetan ingredient name signifies a variety of therapeutically fitting botanical items.
According to modern botanical nomenclature, these items
may appear quite different, sometimes even from different
species, genera or families (see again Blaikie 2014; Czaja
2017; Sabernig 2011 for examples).
One example is the agaru (a gar ru) recipe family. The
eponymous component agaru is most commonly identified as the wood of Aquilaria species (e.g., Arya 1998;
Meyer 1988). Contemporary materia medica literature
identifies the red type agaru armar (a ga ru ar dmar) also as
the woods from Cinnamomum or Syringa spp. (Gawé Dorjé
1995). Moreover, plants such as Caryopteris mongholica
Bunge or Carum carvi L. (seeds) are also used.4 All variants
carry different explanations for why they can be used in a
certain formula. In several instances, two or three types of
agaru (black, white, and red) are used together as a group,
sometimes noted as distinct ingredients and sometimes

used in combined form.5 The red type is particularly good
for wind-heat conflict disorders (rlung tshad), even though
its action profile overlaps with the other types of agaru. All
clearly differ chemically and analytically from each other,
but according to the different local traditions have enough
similar qualities to act effectively in multicomponent
formulas such as Agar 8 or Agar 35.
It remains an open task for fieldwork to investigate the
dynamic use of formulas in Sowa Rigpa, specifically the
use of different variants of a formula which have been in
use in different regions during specific time periods (but
see Blaikie 2015; Gerke 2018; Nianggajia 2015; van der Valk
2019). As emphasized earlier, this research should not be
directed towards finding the ‘real’ or ‘original’ formula.
Rather, important topics to consider are which formulas
and variants are used, what their specific medical usages
are, patient and practitioner experiences and narratives,
and the impact of specific regional lineages. Additional
important questions are: Where is the border of activity?
When is the variability overstretched (i.e., when is the
formula not suitably active anymore)?
The Advantages of Plasticity
Botanical plasticity has specific advantages, especially
as part of multicomponent preparations. It allows for
historical continuity of practice and addresses some of the
following challenges of the Anthropocene:
1. Environmental challenges, changes of natural
habitats in response to climate change;
2. Challenges of species extinction and protection
of endangered species; and
3. Regulatory demands, where modern policies
respond to toxicological issues, restrict the use of
potentially hallucinogenic plants (e.g., cannabis,
opium, betel nut), or apply stricter rules in the
interface of medicinal drugs, food supplements, and
traditional use of formulas.
Because of the time-tested functional assignment of
materia medica, the botanical plasticity is linked to a
consistent action profile. It is the network of the functional interactions which remains therapeutically stable
and robust despite the variable botanical composition.
However, how do we understand this when chemical
analyses would show significantly different chemical
profiles for the different variants? From the perspective of modern pharmacology, one plant on its own is
already a multi-substance chemical mixture subject to a
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Figure 1. Schematic representation of the
network hierarchy in the human organism.
Numerous signal pathways make connections
between the hierarchies. A hypothetical
pleiotropic signature of a Tibetan multicompound formula is indicated in red, which
includes all the involved signal pathways in the
body. As the pathways approach the more basic
levels (lower complexity), they appear broader,
indicating the nonspecific binding capacity of
complex herbal mixtures towards a variety of
targets. Figure slightly adapted.
(Schwabl et al., 2013)

certain natural variability according to environmental
factors (such as harvesting time, climatic conditions, soil
contents, and collection practices). Because of the variety
of the many chemical molecules present in one plant, its
activity can be approached as a typical multi-target drug,
addressing a whole range of receptors in the body. Tibetan
formulas, usually composed from a minimum of three to
many more ingredients, are thus extreme examples of
such multi-target drugs. The natural components of such a
formula can be described as having the following properties (Efferth and Koch 2011):
1. multiple modes of action on different system
levels;
2. presence of single chemical components in low
concentrations;
3. lack of total blockage, stimulation, or saturation
of bodily receptors due to the low concentration of
each single component;
4. a pleiotropic mode of action (i.e., the simultaneous activation of multiple network points); and
5. weak chemical bonds and non-specific actions of
components, addressing a broad range of receptors
with relatively few side effects.
With this pleiotropic characteristic, the activity profile
of a formula expresses itself on the different levels of
the organism: from the systemic level down to organs,
tissues, cells, and subcellular components such as genes
and networks of metabolic pathways. In the case of the
multicomponent mixtures of Tibetan medicine, a very
broad pattern based on weak interactions in the lower
system levels is to be expected. The links and nodes of such
a network represent the pleiotropic signature of the formula
(cf. Schwabl et al. 2013; Figure 1).
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Due to the multifunctionality of the pharmacologically
active agents in a medicinal plant, the action profile
usually results in an overlap of three levels of action (Saller
et al. 2011):
1. Specific: orientation to symptoms/symptom
complexes or specific diseases, usually effected via
defined ligand-receptor interactions;6
2. Adaptogenic: orientation to the entire organism
and its modes of reaction, which is a non-specific,
usually tonifying activity that increases the viability and resilience of the organism; and
3. Systemic: orientation to basic disorders (e.g.,
inflammatory processes) where the action is exerted on non-localized, systemic processes on lower
cellular or metabolic levels.
To understand the activity of herbal drugs, the adaptogenic and systemic parts are most relevant. They act due
to their multifocal, multi-target properties and are mostly
non-selective and with broad biological activity. This
profile offers significant benefits since many diseases are
based on complex interactions of numerous targets. Such
multi-target and pleiotropic properties may be beneficial
for cases of multi-morbidity (i.e., complex combinations
of often chronic diseases). The weakly active compounds
attack various cellular targets, which differs from the
strong selectivity of classical chemical pharmaceuticals
with highly concentrated active compounds. If necessary, non-selective multi-target drugs can be combined
with selective mono-target drugs. Herbal preparations
have ‘group effects’ (e.g., anti-inflammatory, as a ‘system
property’) and adaptogenic effects in addition to the
directly indication-related effects (Saller and Rostock
2012). In Tibetan menjor theory, this higher-order activity
is for instance reflected in the ‘warming’ (drod skyed pa)

or ‘cooling’ (bsil ba) nature of Tibetan formulas or in
humoral terminology such as ‘dispels [excess] wind’ (rlung
sel). Further aspects in the composition of a Sowa Rigpa
formulation are the expected additive, synergistic, and
partially antagonistic effects (cf. Gerke 2018; van der Valk
2019; Tidwell and Nettles 2019). Substances are used that
support the main effect, while others neutralize any potentially irritating effects of other ingredients.
If one integrates these characteristics and the three levels
of action into a network, it becomes apparent that each
plant has a characteristic signature. This is why they are
also referred to as ‘network remedies’ (Gertsch 2011). Due
to their pleiotropic character, this pattern is wider and
has many weak connections. Chemical mono-substances
act much more specifically, with a narrow range of strong
chemical connections (Butler 2019). Complex multi-component formulations such as those found in Sowa Rigpa
have a pronounced multi-target modality and associated
pleiotropy. This is not only because of the higher diversity
of components involved, but also due to empirical testing
over generations combined with intricate systematic
theories and compounding methods. These combination
preparations may be particularly suitable as a systemic
base therapy, for instance combined with highly selective drugs and/or in multi-morbid patients. Since Sowa
Rigpa formulas—in all their variants—were used to treat
specific diseases and nyépa imbalances over a long period
of history, this consistent use provides us with a basis for
a time-tested evidence of efficacy (as passed on through
different lineages). Each variant of a formula is related
to a network of functional interactions which act on the
numerous targets of the organism, and it is the network
of functional interactions that remains robust despite
different botanical species and chemical structures. The
different variants of a formula can thus be said to have a
similar pleiotropic signature.
The Correspondence of Illness and Medicine
Living systems, including the human organism, can be
described as networks of interacting parts that comprise
different information and control various circuits. The
ultimate goal of such autonomous systems is homeostasis, or the maintenance of the integrity of the system
under various external and internal influences (Varela
1979; see also Theise 2005).7 The elements in the human
organism consist of independent sub-networks, which in
their totality can be identified as a hierarchy of networks
(Auger 1988). The system levels differ according to the
internal bond strength, the characteristic reaction time,
and the type and number of signals that can be processed.

The semiotic interaction potential,8 the repertoire of
processable or answerable signals, defines the possible
interactions with the system. The more complex a system,
the greater its repertoire. In choosing a therapeutic intervention and planning a treatment protocol, the nature of
the therapeutic signals (manual, invasive, pharmacological, narrative) and their sequence must correspond to
the semiotic capacity of the system. From the perspective
of systems theory, any disease can be interpreted as a
typical signature of the complex system or ‘organism,’
which is connected to its basic structure and dynamics
(e.g., genetic, epigenetic, environment, way of life, age,
gender). Most diseases do not develop according to a
simple, linear path, but instead affect the entire network.
This is especially valid considering new findings in systems
biology and the ‘omics-sciences’ (see for instance Buriani
et al. 2012 for its application to Chinese medicine). These
new scientific branches have begun to decipher the human
genome (genomics), extending into epigenomics (considering cellular feedback on the genome), and metabolomics
(i.e., the study of the metabolic pathways).
The formation and progression of atherosclerosis, for
instance, is influenced by network elements and exogenous risk factors. These include the basic genomic setup,
the metabolome with different cell types and organ
systems (Ghazalpour et al. 2004), and the epigenome.
Accordingly, biomedical diagnostic and therapeutic
approaches are highly diversified. On the one hand, they
include physiological systems and organs such as the
cardiovascular system, the regulation of blood pressure,
coagulation, glucose-insulin levels, and plasma lipids. At
the cellular level, they also include issues such as chronic
inflammation, hormonal balances and imbalances, endothelial functions, and the role of adipose (i.e., fat) tissues.
These exogenous and endogenous aspects of a disease
signature are to be matched with the reactive capacity of
the network organism, which are then included in an individualized therapy profile. By applying this systemic view
to the empirical use of a Tibetan formula, we can speculate
on the correspondence between the signature ‘illness’ and
the signature ‘medicine.’ In the case of atherosclerosis,
the biomedical signature of such a formula is found in its
anti-inflammatory, anti-oxidative, and circulation-promoting properties. The Sowa Rigpa practitioner, on the
other hand, also includes lifestyle factors, such as nutritional status, climatic conditions, and patterns of activity,
as well as the results of subtle diagnostic methods such as
pulse reading or urine analysis. In the Sowa Rigpa framework, a patient with (from a modern biomedical view)
atherosclerotic symptoms shows a profile of increased
heat (tripa) in the blood system and at the same time
HIMALAYA Volume 39, Number 1 | 213

reduced mobility (lung). From a therapeutic perspective,
this requires a drug that has ‘cooling’ and ‘stimulating’
effects on the blood circulation (Schwabl and Vennos 2015;
Vennos et al. 2013). This demonstrates a preliminary correspondence of the signature of the Tibetan formula with the
disease pattern within the coordinates of Sowa Rigpa.
The line of argument presented here allows us, at least in
principle, to investigate the functional profile of a formula
in both reference frames: biomedical science and Sowa
Rigpa. Therapeutic intervention must fit to the semiotic
capacity of the system, with each disease state offering
a complex set of possible interventions. Tibetan medical
practitioners attend to this therapeutic complexity with
their individualized repertoire of different medicines and
interventions, relying on a systemic analysis of the bodymind through the nyépa framework. Since actual variants
of a textual formula can have the same semiotic signature,
the chemical materiality of a formula is secondary—it is
fluid. The functional description of the activity of a medicine in either reference frame prevails over the material,
substance-based definition of a formula. The plasticity of
the herbal components is characterized by their non-specific mode of action, which dissolves the boundaries of
their individual functional profiles. That is, multi-compound herbal mixtures have a pleiotropic mode of action.
The more the specificity (connected to its specific chemical
materiality) is dissolved, the more the semiotic capacity of
the component prevails, and the more important are the
systemic and adaptogenic activities of the mixture. Other
factors further enrich the semiotic signature, including
the sensory characteristics of the formula, the mode of
application, and the patient-doctor interaction. Still,
the pharmakon—the formula in its entirety—remains the
centerpiece of the semiotic interaction.
Conclusion
In multi-compound Sowa Rigpa formulas, one ingredient
can be represented by a variety of materials without
changing the signature of the formula. This botanical plasticity, while retaining the same profile of action, allows the
Tibetan medical physician to respond to difficulties in raw
material supply as well as to the regional flora and local
conditions without altering the essence of the formula.
The practice in Tibetan pharmacology to choose among
a variety of species while composing a specific formula
consequently leads to a different notion of the principle
of ‘active substance.’ The variants of the formula possess
a similar action profile and pleiotropic signature, which
cannot be traced back to an identical chemical molecular
pattern. Due to the cross-linking of the interactions of
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the many constituents, Tibetan formulas act as network
drugs. Looking at the semiotics of a chronic diseased state,
network drugs are particularly suitable for multi-morbid
patients, either by treating specific symptom complexes or
as a systemic therapy in combination with selective drugs.
The practices of Asian medical traditions are still poorly
understood in the current biomedical, pharmaceutical
and regulatory environment, and are not adequately
depicted in official pharmacopoeias. The fixation on rigid
ingredient identifications and recipes espoused by the
global apparatus of modern biomedical science increasingly restricts the available repertoire of medicinal plants.
Sowa Rigpa is designed to react with great flexibility to
various challenges. Unfortunately, however, the quest
for standardization continues to be followed, even in
publications from the Tibetan medical community and by
regulatory authorities. The current pharmaceutical regulatory environment is inadequately informed and even
hostile towards the idea of plasticity. The main regulation
on traditional herbal medicines in Europe (EC 2004), for
instance, explicitly demands a documented continuous
use of an unchanged composition over a period of at least
thirty years to enable market registration (Schwabl 2009).
This reductionist approach, based on the quest for molecular ‘active substances,’ does not do sufficient justice to the
inherently functional approach of Tibetan pharmacology.
A renewed focus on the botanical plasticity and pleiotropic
signatures of Sowa Rigpa formulas raises interesting
questions for further research. Can the limits of functional
variation be defined? How can we better understand the
dynamic spectrum of activity of Tibetan medical formulas?
The herbal network pharmacology perspective laid
out here can perhaps serve as a rough translation tool,
an imperfect conceptual bridge between sciences that
inspires innovative interdisciplinary work between the
medical humanities and sciences. This systemic framework
can and should be expanded to include psychological,
social, historical and geographical semiotic layers. While
remaining attentive to the limitations of and the political-economic stakes involved in the emerging ‘Asian
Medicine/Systems Biology interface’ (Scheid 2016), we
recognize the need for open-ended theoretical models and
regulations that allow Asian medical traditions to flourish
more on their own terms, as well as in contexts usually
dominated by biomedicine. To this end, nuanced engagements with Tibetan pharmacology and Asian science and
technology in general have much to offer.
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3. When and where specimens are harvested further
allows practitioners to accentuate certain qualities for
therapeutic effect. An Amdo-based variant (which might
also be a botanically different species, sub-species, or
variety) could be gathered later than a Lhasa-based
reference specimen, for instance, to maintain isomorphic
qualities. Thanks to Tawni Tidwell for pointing this out.
4. Interview with Dr. Lobsang Dhondup Dripatsang at
Padma AG, Switzerland, January 2018.
5. See for example the formula for Agar 35 provided by
Dash (1994: 215-217), who mentions all three types of agaru.
6. Interactions between a molecule and a protein on or
within a target cell. In the classical view of drug action this
is called the ‘lock-and-key’ model. Specific drugs are ‘keys’
that ideally only fit a single biological target or ‘lock.’
7. Francisco Varela and Humberto Maturana introduced
the system-theoretic concept of autopoiesis to model
living beings. Varela then further refined this approach
by introducing the concept of autonomy: living systems
reproduce and create their own system components
(autopoiesis) while maintaining their identity (autonomy).
The concept of autonomy allows one to define the signals
which can be interpreted by the system in a meaningful
manner, and the repertoire of possible responses to these
external stimuli.
8. In analogy to Eco (1992). In abstract terms, living
structures (as autonomous systems) have a certain
repertoire of communication with the environment in
terms of signals and responses. This process as well as the
classification of signs is the field of semiosis, which can also
be applied to the repertoire of therapeutic interventions
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